Stay up to date with Aimmune Therapeutics Inc stock news. © Copyright 2020 Morningstar, Inc. All rights reserved. Real-time trade and investing ideas on Aimmune Therapeutics AIMT from the largest community of traders and investors. [ ]10 Best Stocks for 2020: Don’t Take Your Seat Belt Off Just YetBest Stocks for 2020: Expect Aimmune Stock to Come Back in Full ForceBioCryst Berotralstat PDUFA, And Other News: The Good, Bad And Ugly Of BiopharmaAimmune Shares Look Cheap On A Discounted Cash Flow BasisAimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceFood Allergy Diagnosis and Treatment Market 2020 Growth Probability, Key Vendors and Future Scenario Up To 2026Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational HighlightsThe Global Allergy Immunotherapy Market is expected to grow from USD 3,283.67 Million in 2019 to USD 5,084.71 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.56%Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational HighlightsFull Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent HealthGlobal Peanut Allergy Therapeutics Market 2020 by Key Players, Regions, Type and Application, Forecast to 2025Allergy Immunotherapy Market Share, Growth Forecast- Global Industry Outlook 2020-2026 | Aimmune Therapeutics, Hollister Allergy, LETIPharma, etc.Aimmune Appoints Narinder Singh as Executive Vice President of Technical OperationsTherapeutic Vaccines Market Share, Size Global Regional Overview, Opportunities, Trends, Global Growth,Impact of Covid-19 on Industry, Leading Company Analysis, And Key Country Forecast to 2025Global Peanut Allergy Therapeutics Market 2020 Industry Emerging Trend, Market Players, Revenue Insights to 2026Global Therapeutic Vaccines Market expected to reach CAGR of 6.91% , Future prospect & Industry growth till 2023Allergy Immunotherapy Market Share and Growth Factors Impact Analysis 2020 - 2027Codexis Announces the Election of New Directors at its Annual Meeting of StockholdersNew Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut AllergyNew Data Show Patients Are Highly Satisfied With and Confident in the Efficacy of Daily Treatment With PALFORZIA™ After Nine MonthsAimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers Allergy Immunotherapy Market 2020 | Report Highlights the Competitive Scenario with Impact of Drivers And Challenges 2026 Aimmune stock fell below its 50-day line . Hargreaves Lansdown is not responsible for an (2.58%) Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.Investing legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free.Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceMarket Update: BKNG, GOLD, CLS, MO, MRK, FBHS, ZTS, CTVADiscover new investment ideas by accessing unbiased, in-depth investment researchNasdaqGS - NasdaqGS Real Time Price.